Higher levels of the complement pathway protein C4a des-arg have been described previously in the CSF of patients with AD [20, 26], and our group also found increased levels of the C4a peptide lacking the C-terminal arginine in MCI patients who progressed to AD [19]. Here, DES is linked to Alzheimer disease.